CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial
Nirali N. Shah(National Institutes of Health), Terry J. Fry(University of Colorado Anschutz Medical Campus), Alina Dulau‐Florea(National Institutes of Health), Steven L. Highfill(National Institutes of Health), Dalia Salem(National Institutes of Health), Constance M. Yuan(National Cancer Institute), Bonnie Yates(National Institutes of Health), Seth M. Steinberg(National Institutes of Health), Cindy Delbrook(National Institutes of Health), Staci Martin(National Institutes of Health), Jianjian Jin(National Institutes of Health Clinical Center), Anusha Ponduri(National Institutes of Health), Amanda K. Ombrello(National Human Genome Research Institute), Pamela L. Wolters(National Cancer Center), Maryalice Stetler‐Stevenson(National Cancer Institute), Haris Qureshi(National Institutes of Health), Haneen Shalabi(Center for Cancer Research), David F. Stroncek(Yale University), Haiying Qin(National Institutes of Health), Lauren Little(Rush University), Crystal L. Mackall(Parker Institute for Cancer Immunotherapy), Hao‐Wei Wang(Fu Jen Catholic University), Sandhya R. Panch(University of Washington), Minh Tran(National Institutes of Health Clinical Center), Leah Hoffman(Medical College of Wisconsin)
Cited by 422
Related Papers
Early-Onset Stroke and Vasculopathy Associated with Mutations in ADA2
|New England Journal of Medicine|2014|889
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2016|817
IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion
|Genes & Development|2010|744
Programming CAR-T cells to kill cancer
|Nature Biomedical Engineering|2018|435
Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer
|Clinical Cancer Research|2005|371